Craig R. Miles - Patent and Trademark Attorney

Patent and Trademark Attorney

CRAIG R. MILES has practiced intellectual property law since 1999. He founded CR MILES P.C. in 2003 to focus on international and domestic patent, trademark, and copyright law. In his practice as an intellectual property attorney he has prepared, filed, and successfully prosecuted hundreds of patent and trademark applications before the United States Patent and Trademark Office as well as internationally by way of the Patent Cooperation Treaty and Paris Convention.

Prior to his practice as an intellectual property and patent attorney in Colorado, he was a research scientist in the biomolecular sciences at the crossroads of chemical, biological, physical, and computational sciences focusing on the molecular understanding of cellular function. He was a founder of Cytel Corporation in La Jolla, California, which developed research methods to assess molecular recognition and regulation. As an Assistant Professor at Colorado State University, he was the Director of facilities for the synthesis and assessment of peptide, protein, and nucleic acid structures.

Communication Center

Areas of Practice

Bar Admissions

Education

Professional Associations and Memberships

Published Works

Published Works:

"Interaction between a processed ovalbumin peptide and Ia", Proc. Nat. Acad. Sci. USA 83, 3968 (1986).
"Isolation and characterization of cDNA clone for porcie thyroid peroxidase", FEBS 208, 392 (1986).
"An introduction to the use of hydrogen fluoride in peptide synthesis", Applied Biosystems User Bull. 11 (1987);
"The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides" Science 235, 1353 (1987);
"Peptide Sequence of T-cell receptor δ and γ are identical to predicted X and γ proteins", Nature 330, 572 (1987);
"Structural characteristics of an antigen required for its interaction with Ia and recognition by T-cells", Nature 328, 395 (1987);
"Biochemical characterization of proteins that co-purify with class II antigens of the murine MHC", J. Immunol. 141, 1930 (1988);
I-Ad-binding peptides derived from unrelated protein antigens share a common structural motif", J. Immunol. 141, 1930 (1988);
"Structural analysis of peptides capable of binding to more than one Ia antigen", J. Immunol. 142, 35 (1989);
"Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis", Proc. Nat. Acad. Sci. 86, 3296 (1989);
"Structural requirements for the interaction between peptide antigens and I-Ed molecules", J. Immunol. 143, 3289-3294 (1989);
"Effect of conformational propensity of peptide antigens in their interaction with MHC class II molecules", J. Immunol. 143, 1268-1273 (1989);
"Induction by class I MHC-restricted peptide-specific cytolytic T lymphocytes by peptide priming in vivo", J. Immunol. 143, 1094-1100 (1989);
"Structural requirements and biological significance of interaction between peptides and the major histocompatibility complex" Philos-trans-R-Soc. London (Biol), 545-552 (1989);
"The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo", J. Immunol. 144, 2493-2498 (1990);
"Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice using a peptide with high affinity for IAs molecules" J. Immunol. 145, 1687-1693 (1990);
"A novel approach to the generation of high affinity class II-binding peptides" J. Immunol. 145, 1809-1813 (1990);
"Characterization of the specificity of peptide binding to four DR haplotypes", J. Immunol. 145, 1799-1808 (1990);
"Structural requirements for peptides that stimulate a subset of δ ST cells" J. Immunology (1994).

Meet Us

Patent and Trademark Attorney

Meet Us